title: Heparin bridging in warfarin anticoagulation therapy initiation could increase bleeding in non-valvular atrial fibrillation patients: a multicenter propensity-matched analysis.
abstract: BACKGROUND
  The efficacy of heparin-bridging therapy during the initiation of oral anticoagulation therapy (OAC) in non-valvular atrial fibrillation (NVAF) is unclear.
  
  
  OBJECTIVE
  To evaluate the efficacy and the safety of heparin-bridging therapy during OAC initiation in NVAF patients.
  
  
  METHODS
  This study included 5327 consecutive warfarin-naïve NVAF patients who received OAC that was initiated with (n = 1053) or without (n = 4274) heparin bridging at four tertiary hospitals. Stroke and bleeding events within 30 days of OAC were evaluated.
  
  
  RESULTS
  While there was no difference in the incidence of stroke (0.5% vs. 0.3%, P = 0.381), major bleeding rate (0.9% vs. 0.3%, P = 0.004) was higher in heparin-bridged than in non-bridged patients. This trend remained in the propensity score-matched population (stroke 0.5% vs. 0.6%, P = 0.762; major bleeding 0.8% vs. 0.1%, P = 0.019). A high CHA2 DS2 -VASc score was an independent predictor for stroke, whereas bridging therapy had no beneficial effect in preventing stroke regardless of CHADS2 or CHA2 DS2 -VASc scores. The HAS-BLED score had a predictive value for major bleeding (odds ratio 1.80, 95% confidence interval 1.11-2.92, P = 0.018), and heparin-bridging therapy was associated with a higher major bleeding rate (odds ratio 4.44, 95% confidence interval 1.68-11.72, P = 0.003), especially in patients with a HAS-BLED score of ≥ 1.
  
  
  CONCLUSIONS
  The heparin-bridging therapy increased bleeding without the benefit of preventing stroke at the initiation of OAC in NVAF. Our data suggest that heparin bridging should not be considered at the initiation of OAC in NVAF patients.
authors.affiliation: Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
authors.forename: T-H
authors.initials: TH
authors.lastname: Kim
authors.forename: J-Y
authors.initials: JY
authors.lastname: Kim
authors.forename: H-S
authors.initials: HS
authors.lastname: Mun
authors.forename: H-Y
authors.initials: HY
authors.lastname: Lee
authors.forename: Y H
authors.initials: YH
authors.lastname: Roh
authors.forename: J-S
authors.initials: JS
authors.lastname: Uhm
authors.forename: H-N
authors.initials: HN
authors.lastname: Pak
authors.forename: M-H
authors.initials: MH
authors.lastname: Lee
authors.forename: B
authors.initials: B
authors.lastname: Joung
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects*; D001281:Atrial Fibrillation / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D016009:Chi-Square Distribution; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced*; D006493:Heparin / Q000008:administration & dosage* / Q000009:adverse effects*; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D057216:Propensity Score; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D020521:Stroke / Q000517:prevention & control; D013624:Taiwan; D062606:Tertiary Care Centers; D013997:Time Factors; D016896:Treatment Outcome; D014859:Warfarin / Q000008:administration & dosage* / Q000009:adverse effects*
chemical_list: D000925:Anticoagulants; D014859:Warfarin; D006493:Heparin
keywords: atrial fibrillation; hemorrhage; heparin; stroke; warfarin